Expert Speaker Faculty:


Anne-Ulrike Trendelenburg
Director, Head of MSD Cambridge, Novartis Institutes for Biomedical Research (NIBR), Musculoskeletal Disease Area (MSD)
Novartis

Barry Byrne
Associate Chair of Pediatrics & Director, Powell Gene Therapy Center
University of Florida




Jeffrey Chamberlain
Professor, Departments of Neurology, Medicine, and Biochemistry
University of Washington


Kevin Flanigan
Director, Center for Gene Therapy, Nationwide Children’s Hospital; Professor
The Ohio State University

Kevin Whittlesey
Vice President, Translational Medicine, Project Leader for Neuromuscular Disorders
4DMT




Luk Vandenberghe
Grousbeck Associate Professor in Gene Therapy, Harvard; Co-Founder & Chief Science Advisor
Affinia Therapeutics




Petra Kaufmann
Senior Vice President, Clinical Development/ Analytics & Translational Medicine
Novartis Gene Therapies

Michael Binks
Vice President & Head of Rare Disease Clinical Research, RDRU, Worldwide Research & Development
Pfizer






